Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Olopatadine Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 17 USDMF, 9 JDMF, 6 EU WC, 14 KDMF, 14 NDC API, 25 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

12 Drugs in Development

12 Drugs in Development

INTERMEDIATES

15 Intermediate Suppliers

15 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

89 FDF Dossiers, 36 FDA Orange Book, 13 Europe, 13 Canada, 5 South Africa, 22 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION/DROPS;OPHTHALMIC - EQ 0.7% BASE, SOLUTION/DROPS;OPHTHALMIC - EQ 0.1% BASE, SOLUTION/DROPS;OPHTHALMIC - EQ 0.2% BASE, SPRAY, METERED;NASAL - 0.665MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 3 DKSH, 2 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 1 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 5 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 10 BASF, 1 Clariant, 10 Corel Pharma Chem, 1 Finar, 6 Gangwal Chemicals, 4 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 14 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 4 Microlex e.U, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 3 Roquette, 6 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives, 31 Fillers, Diluents & Binders, 19 Controlled & Modified Release, 14 Direct Compression, 12 Taste Masking, 12 Chewable & Orodispersible Aids, 11 Solubilizers, 11 Parenteral, 10 Granulation, 9 Disintegrants & Superdisintegrants, 8 Co-Processed Excipients, 7 Film Formers & Plasticizers, 6 Thickeners and Stabilizers, 5 Empty Capsules, 4 API Stability Enhancers, 4 Rheology Modifiers, 4 Vegetarian Capsules, 3 Topical, 2 Coloring Agents, 1 Surfactant & Foaming Agents, 1 Emulsifying Agents, 1 Lubricants & Glidants

DIGITAL CONTENT

49 News #PharmaBuzz

49 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 12 Regulatory FDF Prices, 19 Annual Reports

MARKET PLACE

19 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

17 US Patents, 1 US Exclusivities, 6 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 Others

3 Others

ANALYTICAL

3 Analytical Methods

3 Analytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Name of the Firm	Written Confirmation No.	Product Name	Issue Date	Valid Till	Address of the Firm
04/06/2025	FDC	India	M/s FDC Ltd	WC-0055n	Olopatadine Hydrochloride IH/IP/USP	2022-06-18	2025-07-07	Plot No.-19 & 20/2, MIDC, Dhatav -402116, Taluka: Roha, District: Raigad
04/06/2025	Indoco Remedies Limited	India	M/s Indoco Remedies Limited	WC-0152n	Olopatadine Hydrochloride USP	2022-08-01	2025-07-15	R-92,93, First Floor, TTC Industrial Area MIDC, Thane Belapur Road, Navi Mumbai, Thane-400701, Maharashtra India

Olopatadine Hydrochloride

Olopatadine Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers

17 USDMF

9 JDMF

6 EU WC

14 KDMF

14 NDC API

25 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

12 Drugs in Development

INTERMEDIATES

15 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

89 FDF Dossiers

36 FDA Orange Book

13 Europe

13 Canada

5 South Africa

22 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION/DROPS;OPHTHALMIC - EQ 0.7% BASE

SOLUTION/DROPS;OPHTHALMIC - EQ 0.1% BASE

SOLUTION/DROPS;OPHTHALMIC - EQ 0.2% BASE

SPRAY, METERED;NASAL - 0.665MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

13 SPI Pharma

3 DKSH

2 Faran Shimi Pharmaceutical

4 Boai NKY Pharmaceuticals Ltd

1 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 ACG Worldwide

5 Actylis

1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

10 BASF

1 Clariant

10 Corel Pharma Chem

1 Finar

6 Gangwal Chemicals

4 Ideal Cures Pvt Ltd

1 Ingredion Pharma Solutions

14 Kerry

3 Kima Chemical

6 Lonza Capsugel

4 Microlex e.U

2 Novo Excipients

1 Pharmatrans-Sanaq

2 Pluviaendo

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

3 Roquette

6 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

2 The Dow Chemical Company

1 Ulanqab Kema New Material

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives

31 Fillers, Diluents & Binders

19 Controlled & Modified Release

14 Direct Compression

12 Taste Masking

12 Chewable & Orodispersible Aids

11 Solubilizers

11 Parenteral

10 Granulation

9 Disintegrants & Superdisintegrants

8 Co-Processed Excipients

SPRAY, METERED;NASAL - 0.665MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons